Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents

PHASE4CompletedINTERVENTIONAL

Enrollment

31,041

Participants

Timeline

Start Date

July 24, 2021

Primary Completion Date

March 24, 2023

Study Completion Date

August 31, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

Experimental Group

SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection

Trial Locations (1)

Yongping Center for Diseases Control and Prevention, Dali

All Listed Sponsors

lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY

NCT04992208 - Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents | Biotech Hunter | Biotech Hunter